替莫唑胺与司莫司汀治疗恶性脑胶质瘤的疗效分析  

Curative effect analysis of temozolomide and semustine in treatment of onpars encephalica spongioblastoma

作　　者：黄韶华[1] 梁俊君[1] 徐德玲[1] 闫倩[1] 辛海滨[1] 

机构地区：[1]山东省安丘市人民医院神经外科,山东安丘262100

出　　处：《中国当代医药》2013年第5期69-69,71,共2页China Modern Medicine

摘　　要：目的探讨替莫唑胺与司莫司汀治疗恶性脑胶质瘤的临床效果。方法选择100例恶性神经胶质瘤患者,随机分为对照组及观察组,观察组使用替莫唑胺治疗,对照组使用司莫司汀治疗,治疗期间监测患者肝肾功能及血常规变化,比较两组患者临床疗效及并发症情况。结果观察组有效率为84.0%,显著高于对照组的48.0%(P<0.05);观察组发生血小板减少、白细胞减少、恶心呕吐和肝肾功能受损的比率均显著低于对照组(P<0.05)。结论替莫唑胺治疗恶性脑胶质瘤能作用于肿瘤细胞增殖的各个时期,具有较好的临床疗效,且不良反应更少。Objective To investigate the clinical effect of temozolomide and semustine in the treatment of onpars en- cephalica spongioblastoma. Methods One hundred cases of patients with spongioblastoma were selected and random- ized into obserbvation group and control group, patients in observation group were taken temozolomicle and patients in control group were taken semustine, liver, kidney function and blood routine detecting were monitored, clinical cura- tive effect and complication were contrasted between observation group and control group. Results Effective power was 84.0% in observation group and was 48.0% in control group, effective power was higher in observation group than that in control group, incidence rate of platelet decreasing, leucocyte decreasing, nausea and vomiting, liver and kidney function injury was lower in observation group than that in control group （P 〈 0.05）. Conclusion Temozolomide has effect in various phase in semustine onpars encephalica spongioblastoma, and has good clinical curative effect and low untoward reaction.

关 键 词：替莫唑胺 司莫司汀 恶性脑胶质瘤 疗效分析 

分 类 号：R739.41[医药卫生—肿瘤]